May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Lucentis or Avastin Enhancement Combined With Macugen Maintenance for Exudative Age Related Macular Degeneration
Author Affiliations & Notes
  • P. H. Scharper, Jr.
    Retina Institute of Hawaii, Honolulu, Hawaii
  • M. J. Tolentino
    University of Pennsylvania, Philadelphia, Pennsylvania
  • M. Bennett
    Retina Institute of Hawaii, Honolulu, Hawaii
  • Footnotes
    Commercial Relationships  P.H. Scharper, None; M.J. Tolentino, Genetech, Pfizer, Eyetech, Novartis, C; Opko, P; QLT, Eyetech, Pfizer, Novartis, R; M. Bennett, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 340. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. H. Scharper, Jr., M. J. Tolentino, M. Bennett; Lucentis or Avastin Enhancement Combined With Macugen Maintenance for Exudative Age Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):340. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine if a pan VEGF-A inhibitor (Avastin/Lucentis) can enhance the efficacy of maintenance therapy with a VEGF-165 inhibitor (Macugen) in order to maximize safety without compromising efficacy in patients with exudative age related macular degeneration.

Methods: : Patients with exudative age related macular degeneration who were treated initially with at least two injections of Macugen followed by at least 1 injection of Avastin or Lucentis then continued on at least 3 Macugen injections were identified from the records of two retina only private practices. Main outcome measure is lines of Snellen visual acuity gained or lost. Secondary outcome measures included number of Avastin or Lucentis injections used, mean visual acuity, and OCT central retina thickness.

Results: : 179 eyes were identified. 88/179 (49%) eyes received Avastin only for enhancement, 58/179 (32%) were treated with Lucentis only and 33/179(18%) of eyes received both Avastin and Lucentis. 59/179 (33%) eyes gained more than 3 lines of vision, 155/179 (87%) eyes did not lose any lines of vision and 170/179 eyes did not lose more than 3 lines of vision. Average follow-up was 7.5 months.

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×